Lung cancer trials in Japan

In Japan 135 Also abroad 2746

135 trials · From ClinicalTrials.gov, checked 14 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
Where
Osaka
Age
18 years and over
People
184 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07602855
Phase 1Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
Where
Chuo-Ku, Hirakata-shi, Kashiwa-shi
Age
18 years and over
People
232 worldwide
Run by
AbbVie
See details and how to joinNCT06858813 · EU 2024-518012-39-00
Phase 1Taking people
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Where
Chuo Ku
Age
18 years to 100 years
People
116 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00
Phase 1Taking people
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Where
Chūōku
Age
18 years and over
People
540 worldwide
Run by
SystImmune Inc.
See details and how to joinNCT05983432
Phase 3Taking people
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Where
Asahikawa, Bunkyō-Ku, Hidaka, Hirakata, Kanazawa, Koto-Ku, Kumamoto, Kurume, Kyoto, Matsusaka, Nagoya, Nishinomiya, Okayama, Omura-shi, Osaka, Sakai, Sendai, Shimotsuke, Tokyo, Wakayama
Age
18 years and over
People
780 worldwide
Run by
Summit Therapeutics
See details and how to joinNCT06767514 · EU 2024-518629-14-00
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Where
Hirakata, Kashiwa, Sendai
Age
18 years and over
People
182 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06855771 · EU 2024-519814-29-00
Phase 1Taking people
AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer
Where
Chuo Ku, Kashiwa, Koto-Ku, Nagaizumi-chō, Nagoya, Sakai
Age
18 years and over
People
102 worldwide
Run by
Chugai Pharmaceutical
See details and how to joinNCT07617337
Phase 3Taking people
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
Where
Bunkyo Ku
Age
18 years to 99 years
People
400 worldwide
Run by
Amgen
See details and how to joinNCT07778316
Phase 1/2Taking people
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Where
Bunkyoku, Kōtoku, Sakai
Age
18 years and over
People
630 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06427941 · EU 2025-524136-19-00
Phase 1/2Taking people
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
Where
Chuo-ku, Hirakata
Age
18 years and over
People
240 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07325136 · EU 2025-524090-16-00
Phase 1/2Taking people
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Where
Chuo Ku
Age
18 years to 100 years
People
280 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06726148 · EU 2024-517281-42-00
Phase 1Taking people
Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
Where
Chuo Ku
Age
18 years and over
People
66 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07630961
Phase 3Taking people
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Where
Chūōku, Fukuoka, Kashiwa, Kōtoku, Niigata, Osaka, Sakai, Sapporo, Sendai, Wakayama, Yokohama
Age
18 years and over
People
582 worldwide
Run by
AstraZeneca
See details and how to joinNCT06350097 · EU 2023-509883-89-00
Phase 1/2Taking people
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
Where
Aichi, Chuo Ku, Fukuoka, Hirakata-shi, Kanagawa, Kashiwa-shi, Koto-ku, Okayama, Osaka, Sendai, Shizuoka
Age
18 years and over
People
244 worldwide
Run by
Taiho Pharmaceutical Co., Ltd.
See details and how to joinNCT04683250
Phase 1Taking people
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Where
Hirakata-shi, Kashiwa-shi
Age
18 years and over
People
220 worldwide
Run by
AbbVie
See details and how to joinNCT07241039 · EU 2025-521607-48-00
Phase 1/2Taking people
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Where
Kashiwa
Age
18 years and over
People
1,109 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT04895709
Phase 3Taking people
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Where
Chūōku, Fukuoka, Hirakata-shi, Kashiwa, Kōtoku, Matsuyama, Nakatogari, Okayama, Osaka, Sakai, Sagamihara, Sapporo, Takatsuki, Wakayama
Age
18 years and over
People
540 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06203210 · EU 2023-509628-16-00
Phase 1Taking people
AB122 Platform Study
Where
Aichi, Chiba, Ehime, Hokkaido, Kanagawa, Osaka, Shizuoka, Tokyo, Wakayama
Age
18 years and over
People
917
Run by
Taiho Pharmaceutical Co., Ltd.
See details and how to joinNCT04999761
Phase 1Taking people
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Where
Chuo Ku, Kashiwa-shi, Nagoya
Age
18 years and over
People
434 worldwide
Run by
Amgen
See details and how to joinNCT07094113
Phase 2Taking people
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Where
Aichi, Nagoya, Chiba, Kashiwa, Miyagi, Sendai, Osaka, Osaka, Osaka, Sakai, Tokyo, Chuo-ku, Tokyo, Koto-ku
Age
18 years and over
People
204 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT05882058 · EU 2023-504247-13-00
Phase 1Taking people
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Where
Kashiwa, Nagaizumi-chō
Age
18 years and over
People
714 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00
Phase 1Taking people
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Where
Kashiwa
Age
18 years and over
People
914 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT06131840 · EU 2023-505858-18-00
Phase 1Taking people
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Where
Chiba, Tokyo
Age
18 years and over
People
710 worldwide
Run by
Incyte Corporation
See details and how to joinNCT06179160 · EU 2023-507091-47-00
Phase 1Taking people
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Where
Okayama, Wakayama
Age
18 years and over
People
220 worldwide
Run by
Amgen
See details and how to joinNCT06598306 · EU 2024-511838-12-00
Phase 1Taking people
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Where
Chuo-ku, Hirakata-shi, Kashiwa-shi, Kobe, Nagoya, Sunto-gun, Wakayama
Age
18 years and over
People
694 worldwide
Run by
AbbVie
See details and how to joinNCT05005403